TLDR: Amgen’s Q3 revenue hits $9.6B, with 12% growth year-over-year. Strong sales from Repatha® and TEPEZZA® boost Amgen’s performance. Amgen reports 25% increase in operating income for Q3 2025. Q3 free cash flow rises to $4.2B, marking a significant improvement. Amgen expects robust growth, with 2025 revenues forecasted between $35.8B-$36.6B. Amgen Inc. (AMGN) experienced a [...] The post Amgen Inc. (AMGN) Stock: Surge as 12% Revenue and Strong Cash Flow Attracts Investor Attention appeared first on CoinCentral.TLDR: Amgen’s Q3 revenue hits $9.6B, with 12% growth year-over-year. Strong sales from Repatha® and TEPEZZA® boost Amgen’s performance. Amgen reports 25% increase in operating income for Q3 2025. Q3 free cash flow rises to $4.2B, marking a significant improvement. Amgen expects robust growth, with 2025 revenues forecasted between $35.8B-$36.6B. Amgen Inc. (AMGN) experienced a [...] The post Amgen Inc. (AMGN) Stock: Surge as 12% Revenue and Strong Cash Flow Attracts Investor Attention appeared first on CoinCentral.

Amgen Inc. (AMGN) Stock: Surge as 12% Revenue and Strong Cash Flow Attracts Investor Attention

2025/11/05 05:55

TLDR:

  • Amgen’s Q3 revenue hits $9.6B, with 12% growth year-over-year.
  • Strong sales from Repatha® and TEPEZZA® boost Amgen’s performance.
  • Amgen reports 25% increase in operating income for Q3 2025.
  • Q3 free cash flow rises to $4.2B, marking a significant improvement.
  • Amgen expects robust growth, with 2025 revenues forecasted between $35.8B-$36.6B.

Amgen Inc. (AMGN) experienced a notable uptick in its stock price, closing at $296.70, reflecting a modest 0.13% gain.


AMGN Stock Card
Amgen Inc., AMGN

The company’s performance in the third quarter of 2025 has drawn attention with a 12% increase in total revenues. With strong product sales and a solid cash flow, Amgen’s robust financial results set a positive tone for future growth.

Strong Revenue Growth and Product Sales Performance

Amgen’s total revenues for Q3 2025 reached $9.6 billion, a 12% increase compared to the previous year. This growth was primarily driven by a 14% increase in volume across its product lines. However, a 4% reduction in net selling prices partially offset the positive trend. Sixteen products posted double-digit sales growth, including key brands such as Repatha and TEPEZZA, reflecting solid demand across various therapeutic areas.

The company’s revenue growth highlights the strength of its portfolio in diverse markets, from oncology to inflammation. Particularly, Repatha® (evolocumab) saw a 40% increase in sales, reaching $794 million. TEPEZZA® (teprotumumab-trbw) also performed strongly, posting a 15% rise, bolstered by higher inventory levels and a favorable pricing strategy. These figures demonstrate the company’s ability to leverage its innovative products for sustained growth.

Operating Income and Cash Flow Surge

Amgen’s GAAP operating income rose by 25%, reaching $2.5 billion, driven by higher revenues and improved operating margins. This translates into a significant increase in operating margin, which improved by 2.5 percentage points, now standing at 27.6%. Non-GAAP operating income increased 8%, totaling $4.3 billion, though the non-GAAP operating margin saw a slight decline to 47.1%.

Cash flow generation also demonstrated a positive trend, with Amgen generating $4.2 billion in free cash flow during the third quarter. This is a marked improvement from the $3.3 billion in the same period last year. The company attributed this increase to favorable working capital changes and lower interest payments, offsetting higher capital expenditures. The surge in cash flow underpins the company’s ongoing ability to fund growth and return to shareholders.

Forward-Looking Outlook and Financial Guidance

For the full year 2025, Amgen expects total revenues to range between $35.8 billion and $36.6 billion. The company forecasts GAAP earnings per share (EPS) to be between $13.76 and $14.60. On a non-GAAP basis, EPS is expected to be between $20.60 and $21.40, signaling strong growth potential moving forward. These projections take into account the impact of existing tariffs but exclude any potential future changes in pricing or tariffs.

Amgen’s leadership, under CEO Robert A. Bradway, has emphasized the company’s focus on expanding access to its medicines and advancing innovative treatments. With a strong portfolio, disciplined investment strategies, and a growing pipeline, Amgen is well-positioned to sustain long-term growth. As the company moves forward, investors will closely monitor how Amgen continues to navigate the competitive landscape and further capitalize on its diverse product offerings.

The post Amgen Inc. (AMGN) Stock: Surge as 12% Revenue and Strong Cash Flow Attracts Investor Attention appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

Franklin Templeton updates XRP ETF filing for imminent launch

Franklin Templeton updates XRP ETF filing for imminent launch

Franklin Templeton, one of the world’s largest asset management firms, has taken a significant step in introducing the Spot XRP Exchange-Traded Fund (ETF). The company submitted an updated S-1 registration statement to the U.S. Securities and Exchange Commission (SEC) last week, removing language that likely stood in the way of approval. The change is indicative of a strong commitment to completing the fund sale in short order — as soon as this month. The amendment is primarily designed to eliminate the “8(a)” delay clause, a technological artifact of ETF filings under which the SEC can prevent the effectiveness of a registration statement from taking effect automatically until it affirmatively approves it. By deleting this provision, Franklin Templeton secures the right to render effective the filing of the Registration Statement automatically upon fulfillment of all other conditions. This development positions Franklin Templeton as one of the most ambitious asset managers to file for a crypto ETF amid the current market flow. It replicates an approach that Bitcoin and Ethereum ETF issuers previously adopted, expediting approvals and listings when the 8(a) clause was removed. The timing of this change is crucial. Analysts say it betrays a confidence that the SEC will not register additional complaints against XRP-related products — especially as the market continues to mature and regulatory infrastructures around crypto ETFs take clearer shape. For Franklin Templeton, which manages assets worth more than $1 trillion globally, an XRP ETF would be a significant addition to its cryptocurrency investment offerings. The firm already offers exposure to Bitcoin and Ethereum through similar products, indicating an increasing confidence in digital assets as an emerging investment asset class. Other asset managers race to launch XRP ETFs Franklin Templeton isn’t the only one seeking to launch an XRP ETF. Other asset managers, such as Canary Funds and Bitwise, have also revised their S-1 filings in recent weeks. Canary Funds has withdrawn its operating company’s delaying amendment and is seeking to go live in mid-November, subject to exchange approval. Bitwise, another major player in digital asset management, announced that it would list an XRP ETF on a prominent U.S. exchange. The company has already made public fees and custodial arrangements — the last steps generally completed when an ETF is on the verge of a launch. The surge in amended filings indicates growing industry optimism that the SEC may approve several XRP ETFs for marketing around the same time. For investors, this would provide new, regulated access to one of the world’s most widely traded cryptocurrencies, without the need to hold a token directly. Investors prepare for ripple effect on markets The competition to offer an XRP ETF demonstrates the next step toward institutional involvement in digital assets. If approved, these funds would provide investors with a straightforward, regulated way to gain token access to XRP price movements through traditional brokerages. An XRP ETF could also onboard new retail investors and boost the liquidity and trust of the asset, similarly to what spot Bitcoin ETFs achieved earlier this year. Those funds attracted billions of dollars in inflows within a matter of weeks, a subtle indication of the pent-up demand among institutional and retail investors. The SEC, which has become more receptive to digital-asset ETFs after approving products including Bitcoin and Ethereum, is still carefully weighing every filing. Final approval will be based on full disclosure, custody, and transparency of how pricing is happening through the base market. Still, market participants view the update in Franklin Templeton’s filing as their strongest sign yet that they are poised. With a swift response from the firm and news of other competing funds, this should mean that we don’t have long to wait for the first XRP ETF — marking another key turning point in crypto’s journey into traditional finance. If you're reading this, you’re already ahead. Stay there with our newsletter.
Share
Coinstats2025/11/05 09:16